York Medical

YM BioSciences, originally founded as York Medical, was a Canadian biopharmaceutical company focused on the development of oncology and hematology therapies. The company's lead candidate was momelotinib (formerly CYT387), a selective small molecule inhibitor of JAK1 and JAK2, which was developed for the treatment of myelofibrosis. Additionally, the company advanced nimotuzumab, a humanized monoclonal antibody targeting the epidermal growth factor receptor (EGFR) for various solid tumors. YM BioSciences was publicly traded on the NYSE MKT and TSX before its acquisition by Gilead Sciences in 2013 for approximately $510 million. The acquisition was primarily driven by the potential of momelotinib to compete in the myeloproliferative neoplasm market.